Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results of a phase II clinical trial. Hazard ratios (95% CI) for radiographic rPFS and OS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback